[EN] ARYL GLYCINAMIDE DERIVATIVES AND THEIR USE AS NK1 ANTAGONISTS AND SEROTONIN REUPTAKE INHIBITHORS [FR] DERIVES D'ARYLE GLYCINAMIDE ET UTILISATION EN TANT QU'ANTAGONISTES DE NK1 ET EN TANT QU'INHIBITEURS DU RECAPTAGE DE SEROTONINE
[EN] ARYL GLYCINAMIDE DERIVATIVES AND THEIR USE AS NK1 ANTAGONISTS AND SEROTONIN REUPTAKE INHIBITHORS [FR] DERIVES D'ARYLE GLYCINAMIDE ET UTILISATION EN TANT QU'ANTAGONISTES DE NK1 ET EN TANT QU'INHIBITEURS DU RECAPTAGE DE SEROTONINE
Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors
申请人:Bernstein Peter
公开号:US20070203139A1
公开(公告)日:2007-08-30
Compounds of the following Formula (I) wherein R
1
and R
2
are independently selected from alkyl or alkenyl or from a heterocyclic ring together with the N to which they are bound, n is 0-2, Ar
1
is (substituted) phenyl and Ar
1
is (substituted) phenyl, naphthyl or tetralin, further as defined in the specification, in vivo-hydrolysable precursors and pharmaceutically acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same. The compounds are neurokinin 1 (NK
1
) receptor antagonists and/or serotonin reuptake inhibitors, with medical indications for depression, anxiety disorders and other conditions.
[EN] ARYL GLYCINAMIDE DERIVATIVES AND THEIR USE AS NK1 ANTAGONISTS AND SEROTONIN REUPTAKE INHIBITHORS<br/>[FR] DERIVES D'ARYLE GLYCINAMIDE ET UTILISATION EN TANT QU'ANTAGONISTES DE NK1 ET EN TANT QU'INHIBITEURS DU RECAPTAGE DE SEROTONINE
申请人:ASTRAZENECA AB
公开号:WO2005100325A1
公开(公告)日:2005-10-27
Compounds of the following Formula (I) wherein R1 and R2 are independently selected from alkyl or alkenyl or from a heterocyclic ring together with the N to which they are bound, n is 0-2, Ar1 is (substituted) phenyl and Ar1 is (substituted) phenyl, naphthyl or tetralin, further as defined in the specification, in vivo-hydrolysable precursors and pharmaceutically acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same. The compounds are neurokinin 1 (NK1) receptor antagonists and/or serotonin reuptake inhibitors, with medical indications for depression, anxiety disorders and other conditions.